Awaiting product image

OncoBEAM EGFR Kit V2 (RUO)

myProbes is a custom design and manufacture service that provides unique fluorescence in situ hybridisation (FISH) probes using the BAC-2-FISH™ process. This process utilises Cytocell’s proprietary BAC clone collection containing >220,000 clones to produce fully quality-assured custom FISH probes for virtually any sequence in the entire human genome.

Add to wishlist
Category:

Enquiry about OncoBEAM EGFR Kit V2 (RUO)

Enter the security code shown above

The Sysmex way of liquid biopsy: Sysmex Inostics OncoBEAM

Sysmex Inostics has been the pioneer in liquid biopsy by implementing OncoBEAM into the clinical routine. OncoBEAM combines emulsion digital PCR with flow cytometry and provides highly sensitive mutation detection based on ctDNA isolated from blood samples. Thereby it offers new possibilities for cancer management & clinical research.

OncoBEAM EGFR Kit V2 (RUO)

  • Detection of 36 EGFR mutations in the human EGFR oncogene exons 18, 19, 20 and 21 (incl. T790M and C797S) using DNA extracted from 2 mL of plasma

  • Highly sensitive BEAMing digital PCR technology combining digital PCR and flow cytometry

  • A more rapid and minimally invasive assessment of EGFR mutations, as compared to tissue biopsy

*For research use only. Any in vitro diagnostic application has not been established by the manufacturer.

The OncoBEAM Advantage

  • Reliable detection of mutations from cell-free DNA that occur at mutant allele frequencies (MAF) as low as 0.01%
  • Viable alternative to tissue testing due to its high concordance (>90%) with tissue biopsy
  • Timely and minimally-invasive analysis of specific mutations before or during targeted therapy
Features & Benefits

The OncoBEAM Advantage

  • Reliable detection of mutations from cell-free DNA that occur at mutant allele frequencies (MAF) as low as 0.01%
  • Viable alternative to tissue testing due to its high concordance (>90%) with tissue biopsy
  • Timely and minimally-invasive analysis of specific mutations before or during targeted therapy
More information